Vepdegestrant: "VERITAC-2 trial in 2L+ ER+ HER2- breast cancer met primary endpoint in ESR1m patients but not in ITT population"; Breast cancer (Pfizer) - Jun 14, 2025 - A Spotlight on Pfizer's Breast Cancer Portfolio
P3 data • Breast Cancer • Estrogen Receptor Positive Breast Cancer • HER2 Negative Breast Cancer • Oncology
|